ASO Visual Abstract: Clinical Outcomes of First-Line Immune Checkpoint Inhibitor-Based Therapy for Postoperative Recurrence After Adjuvant Nivolumab in Esophageal Cancer
本文未提供摘要,请点击“查看全文”查看完整内容。